Previsioni

Acquista	1
Mantieni	0
Vendi	0

Notizie Vai al feed delle notizie

Protagenic Therapeutics reports sharply improved EPS for Q4 2025

Protagenic Therapeutics released results for the quarter ended 31.12.2025 and reported earnings per share (EPS) of 1.14 USD. In the same quarter a year earlier EPS was -3.360 USD, so the company recorded a marked improvement. » Altro su finanzen.net
Protagenic Therapeutics appoints William Nichols Jr. as president

Protagenic Therapeutics has appointed William (Bill) Nichols Jr., effective February 3, 2026, as president. Nichols (51) joins from senior commercial roles at bluebird bio, Dova Pharmaceuticals and Bristol-Myers Squibb. His contract provides a base salary of USD 350,000, an annual target bonus of 40% and stock options amounting to about 1.0% of the fully diluted shares. » Altro su de.investing.com
Protagenic Therapeutics reports quarterly loss of $0.47 per share

Protagenic Therapeutics published on 26.11.2025 the figures for the quarter ended 30.09.2025 and reported a loss per share of $0.47. In the same quarter last year, earnings per share were -$1.96. No further financial details were reported. » Altro su finanzen.net

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2005, Protagenic Therapeutics Aktie ha già distribuito 407.058.437,54 € di dividendi. L'ultimo pagamento è avvenuto a dicembre 2005.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Protagenic Therapeutics Aktie ha registrato ricavi pari a 0 € e un utile netto di -844,33K €

(EUR)	giu 2026	YoY
Ricavi	0	-
Utile lordo	-7,28K	31,71%
Utile netto	-844,33K	80,32%
EBITDA	-834,97K	79,52%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	1,53 Mln €
Numero di azioni	1,81 Mln
Massimo/minimo a 52 settimane	3,93 € - 0,11 €
Dividendi	No
Beta	1,07
Rapporto P/E	0,33
Rapporto PEG	0,00
Rapporto P/B	1,03
Rapporto P/S	0,00

Profilo aziendale

Protagenic Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen, das sich mit der Entdeckung und Entwicklung von Therapeutika zur Behandlung stressbedingter neuropsychiatrischer und stimmungsbezogener Störungen befasst. Die Leitsubstanz ist PT00114, eine synthetische Form von Teneurin carboxy-terminal associated peptide, einem endogenen Signalpeptid des Gehirns, das überaktive Stressreaktionen dämpfen kann. Das Unternehmen hat seinen Sitz in New York, New York.

Nome	Protagenic Therapeutics Aktie
CEO	Garo H. Armen
Sede centrale	Santa Barbara, ca Stati Uniti
Sito web	protagenic.com
Settore	Industria
Industria	Servizi e forniture commerciali
Quotazione in borsa	27/04/2021
Dipendenti	2